Vaccine Therapy in Treating Patients With Liver Cancer

Inclusion Criteria * This study will enroll HLA-A 0201 adults over the age of 18 with history of biopsy-proven HCC and AFP positive by immunohistochemistry or serum AFP levels \> 2 times above the upper limit of normality. Any stage of disease will be eligible. * Both male and female patients may be enrolled. Females of childbearing potential must have a negative pregnancy test prior to treatment. * Patients must be ambulatory with a Karnofsky Performance Status greater than or equal to 70 percent. * No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease. * No evidence of opportunistic infection. * A minimum of 4 weeks must have elapsed since the completion of prior chemotherapy or radiation therapy. * Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0): * Hemoglobin \> 8.5 g/dl (patients cannot be transfusion dependent). * Platelets \> 30,000/mm3 * WBC \> 2,000/mm3 * Absolute Neutrophil Count (ANC) \> 1,000/mm3 * Positive skin test to common antigens (tetanus and/or candida). * Ability to give informed consent and signed informed consent. Exclusion Criteria Patients who meet any one of the following criteria will be excluded from study entry: * Any congenital or acquired condition leading to inability to generate an immune response, including concomitant immune suppressive therapy. The ability to adequately respon…